Dermatology · Mycosis Fungoides

Systemic Therapies for Advanced or Refractory Disease

At a Glance

Advanced or refractory mycosis fungoides and Sézary syndrome may require systemic treatment, such as ECP, targeted medicines, retinoids, or chemotherapy. For selected patients, an allogeneic stem cell transplant is the only established potentially curative option but carries serious risks.

When Mycosis Fungoides (MF) or Sézary Syndrome (SS) progresses beyond the skin—involving the blood, lymph nodes, or internal organs—your care team will transition to systemic therapies. However, systemic agents are not only reserved for spread outside the skin. They may also be selected for widespread or refractory skin disease, severe symptoms, tumors, transformed disease, or particular variants ^[1]^[2]. These treatments travel through your entire body to find and treat cancerous cells.

A Risk-Adapted Approach

Because MF is a chronic, relapsing condition, treatment is risk-adapted. It is common to cycle through different systemic treatments over several years, as responses are often not permanent, and systemic treatments are frequently combined with skin-directed therapies ^[1]^[3]^[4]^[5].

Biological and Targeted Therapies

Unlike traditional chemotherapy, these treatments target specific proteins or processes within the cancer cells or your immune system.

Extracorporeal Photopheresis (ECP): This is a unique “blood-filtering” therapy. Your blood is removed, treated with a light-sensitizing medicine and UVA light to modify T-cells, and then returned to your body ^[6].
- Best For: Erythrodermic MF and Sézary Syndrome, especially when there is measurable blood involvement ^[7].
- Safety & Logistics: It is an immune-modulating treatment. It requires good vein access (sometimes a port) and can cause low blood pressure during the procedure, as well as infection risk at the catheter site ^[8]^[9].
Bexarotene (Targretin): An oral retinoid (vitamin A derivative) that tells cancer cells to stop growing or die ^[10].
- Safety & Monitoring: Bexarotene requires meticulous monitoring. It carries pregnancy/teratogenic risks (severe birth defects). It nearly always causes central hypothyroidism and high triglycerides, requiring thyroid supplements and cholesterol-lowering medications. It also requires liver, pancreatitis, and blood-count monitoring ^[11]^[12].
Mogamulizumab (Poteligeo): An antibody that targets a protein called CCR4 on the surface of cancerous T-cells ^[13]. It is exceptionally effective at clearing cancer cells from the blood ^[14]^[15].
- Safety Warnings: It can cause serious drug eruptions (rashes) and infusion reactions. Crucially, exposure to mogamulizumab shortly before an allogeneic hematopoietic-cell transplantation is associated with an increased risk of severe graft-versus-host disease. A washout interval coordinated by the transplant team is essential.
Brentuximab Vedotin (Adcetris): A targeted therapy for patients whose cancer cells express a marker called CD30. In trials, it showed significantly better response rates than older systemic options ^[16]^[17].
- Side Effects: The main concern is peripheral neuropathy (numbness or tingling in hands and feet), but it can also cause fatigue and low blood counts ^[18].

Other Systemic Options

HDAC Inhibitors (Vorinostat, Romidepsin): These “epigenetic” drugs change how DNA is packaged inside cancer cells to turn on genes that cause the cells to die ^[19]. They are often used as a later-line option for refractory disease ^[14].
Chemotherapy: Traditional “cytotoxic” chemotherapy (like gemcitabine or pegylated liposomal doxorubicin) is generally reserved for later lines of treatment, but it may be selected earlier for rapid, transformed, or otherwise high-risk disease. While it can work quickly, the responses are often short-lived, and the risk of suppressing your immune system is higher than with biological therapies ^[4]^[20].

The Potential for Cure: Stem Cell Transplant

For highly selected patients with aggressive, advanced MF or Sézary Syndrome, an allogeneic hematopoietic stem cell transplant may be considered. This involves replacing your immune system with a donor’s immune system ^[21].

A High-Stakes Choice: It is the only established potentially curative option for selected patients, but it is not guaranteed. It carries substantial risks including severe Graft-versus-Host Disease (GVHD), prolonged infection risk, organ toxicity, infertility, and treatment-related mortality ^[3]^[22]^[23].
Coordination: Early consultation is recommended, but the decision is strictly a specialist-only determination weighing disease control against these profound risks.

In advanced disease, the goal shifts toward a “marathon” mindset—using the least toxic therapy that keeps the disease under control for as long as possible before moving to the next option ^[1].

Common questions in this guide

When is systemic treatment used for mycosis fungoides or Sézary syndrome?

Systemic treatment is used when the disease involves the blood, lymph nodes, or internal organs. It may also be chosen for widespread or difficult-to-treat skin disease, severe symptoms, tumors, or transformed disease, even when it has not spread beyond the skin.

What happens during extracorporeal photopheresis, or ECP?

Blood is removed, treated with a light-sensitizing medicine and UVA light, and returned to the body. ECP is often used for erythrodermic mycosis fungoides or Sézary syndrome with blood involvement, but it requires reliable vein access and can cause low blood pressure or catheter-site infection.

What monitoring does bexarotene require?

Bexarotene commonly causes low thyroid activity and high triglycerides, so patients often need thyroid hormone and lipid-lowering treatment. Doctors also monitor liver function, the pancreas, and blood counts, and people who could become pregnant need strict precautions because bexarotene can cause severe birth defects.

Could brentuximab vedotin be an option for me?

Brentuximab vedotin is considered when tumor cells carry CD30, which can be checked on a biopsy. Its most important side effect is peripheral neuropathy, which causes numbness or tingling in the hands and feet; fatigue and low blood counts can also occur.

What should I know about mogamulizumab before a stem cell transplant?

Mogamulizumab can clear cancer cells from the blood, but receiving it shortly before an allogeneic transplant can raise the risk of severe graft-versus-host disease. The transplant team should plan an appropriate washout interval before transplantation.

Can an allogeneic stem cell transplant cure advanced mycosis fungoides or Sézary syndrome?

For carefully selected patients with aggressive, advanced mycosis fungoides or Sézary syndrome, an allogeneic stem cell transplant is the only established potentially curative treatment. It is not guaranteed and can cause severe graft-versus-host disease, infections, organ damage, infertility, or treatment-related death.

How do doctors decide when to change systemic treatment?

Mycosis fungoides is often managed as a chronic, relapsing illness, so responses may not last and different treatments may be used over time. The care team generally weighs disease control, symptoms, treatment risks, and the least toxic option when deciding whether to continue, combine, or change therapy.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on mycosis fungoides variant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Am I a candidate for 'compartment-specific' therapy, such as mogamulizumab for my blood involvement or skin-directed therapy alongside my systemic treatment?
2.What are the specific side effects of bexarotene, and how will we monitor my thyroid and triglyceride levels during treatment?
3.Has my CD30 expression been tested on a recent biopsy to see if brentuximab vedotin is an option for me?
4.How will we decide when a treatment is no longer working, and what is the next 'line' of therapy we would consider?
5.Given my disease stage, should I have an early consultation with a transplant specialist to discuss allogeneic stem cell transplant as a long-term option?

Key takeaways

Systemic treatments are used when mycosis fungoides or Sézary syndrome involves the blood, lymph nodes, or organs and may also treat widespread, symptomatic, or refractory skin disease.
ECP is particularly useful for erythrodermic disease with blood involvement, while bexarotene, mogamulizumab, brentuximab vedotin, and HDAC inhibitors target specific disease features.
Bexarotene commonly requires thyroid hormone and lipid management, and brentuximab vedotin can cause peripheral neuropathy.
Mogamulizumab requires careful planning before an allogeneic transplant because recent exposure can increase the risk of severe graft-versus-host disease.
Allogeneic stem cell transplant can potentially cure selected aggressive disease but has substantial risks, so specialists weigh it against the possible benefits.

References (23)

1
Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
Hristov AC, Tejasvi T, Wilcox RA
American journal of hematology 2023; (98(1)):193-209 doi:10.1002/ajh.26760.
PMID: 36226409
2
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
Mehta-Shah N, Horwitz SM, Ansell S, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(5)):522-536.
PMID: 32380458
3
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
Latzka J, Assaf C, Bagot M, et al.
European journal of cancer (Oxford, England : 1990) 2023; (195()):113343 doi:10.1016/j.ejca.2023.113343.
PMID: 37890355
4
Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Wilcox RA
American journal of hematology 2017; (92(10)):1085-1102 doi:10.1002/ajh.24876.
PMID: 28872191
5
Mycosis Fungoides, Sézary Syndrome, and Cutaneous B-Cell Lymphomas: 2025 Update on Diagnosis, Risk-Stratification, and Management.
Hristov AC, Tejasvi T, Wilcox RA
American journal of hematology 2025; (100(9)):1603-1628 doi:10.1002/ajh.27735.
PMID: 40495407
6
Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.
Vieyra-Garcia PA, Wolf P
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie 2020; (47(3)):226-235 doi:10.1159/000508479.
PMID: 32595427
7
Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatologic clinics 2015; (33(4)):765-76.
PMID: 26433848
8
Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L, Amitay-Laish I, Gurion R, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2015; (29(12)):2382-9 doi:10.1111/jdv.13243.
PMID: 26299651
9
Extracorporeal photochemotherapy in mycosis fungoides.
Atilla E, Atilla PA, Bozdag SC, et al.
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2017; (24(4)):454-457 doi:10.1016/j.tracli.2017.05.001.
PMID: 28578935
10
Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T, Sugaya M, Tokura Y, et al.
The Journal of dermatology 2017; (44(2)):135-142 doi:10.1111/1346-8138.13542.
PMID: 27543197
11
Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies.
Makita N, Manaka K, Sato J, et al.
Clinical endocrinology 2019; (91(1)):195-200 doi:10.1111/cen.13975.
PMID: 30903705
12
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Cabello I, Servitje O, Corbella X, et al.
Clinical and experimental dermatology 2017; (42(3)):276-281 doi:10.1111/ced.13044.
PMID: 28233333
13
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL, Chen H, de Claro RA, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(24)):7275-7280 doi:10.1158/1078-0432.CCR-19-2030.
PMID: 31366601
14
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, et al.
The Lancet. Oncology 2018; (19(9)):1192-1204 doi:10.1016/S1470-2045(18)30379-6.
PMID: 30100375
15
Efficacy and Safety of Mogamulizumab for Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis.
Lawal A, Rangel AR, Raja A, et al.
Clinical lymphoma, myeloma & leukemia 2026; (26(7)):436-446.e8 doi:10.1016/j.clml.2026.04.014.
PMID: 42236443
16
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future oncology (London, England) 2017; (13(27)):2405-2411 doi:10.2217/fon-2017-0263.
PMID: 28805086
17
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH, Prince HM, Whittaker S, et al.
European journal of cancer (Oxford, England : 1990) 2021; (148()):411-421 doi:10.1016/j.ejca.2021.01.054.
PMID: 33794441
18
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, et al.
Blood advances 2021; (5(23)):5098-5106 doi:10.1182/bloodadvances.2021004710.
PMID: 34507350
19
Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review.
Nayudu K, Thompson BB, Larocca C
Frontiers in medicine 2026; (13()):1912209 doi:10.3389/fmed.2026.1912209.
PMID: 42769261
20
New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Fujii K
Frontiers in oncology 2018; (8()):198 doi:10.3389/fonc.2018.00198.
PMID: 29915722
21
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee.
Damaj G, de Masson A, Dreger P, et al.
Bone marrow transplantation 2025; (60(12)):1565-1573 doi:10.1038/s41409-025-02696-x.
PMID: 41034407
22
Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
Bobrowicz M, Fassnacht C, Ignatova D, et al.
International archives of allergy and immunology 2020; (181(10)):733-745 doi:10.1159/000509281.
PMID: 32690848
23
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
Watson S, Marx JB
Journal of the advanced practitioner in oncology 2019; (10(8)):883-888 doi:10.6004/jadpro.2019.10.8.10.
PMID: 33425472

This page is for informational purposes only and does not constitute medical advice. Your oncology, dermatology, and transplant specialists can tailor treatment choices and explain their risks for your situation.

Guide Contents